Randomized phase II trial of capecitabine (X) versus X plus erlotinib (E) in patients (pts) with metastatic colorectal cancer (mCRC): Differential impact of KRAS.
M. D. Vincent
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
S. Welch
Consultant or Advisory Role - Roche
Honoraria - Roche
D. Soulieres
Consultant or Advisory Role - Roche
Honoraria - Roche
M. S. Sanatani
Honoraria - Roche
F. Whiston
No relevant relationships to disclose
L. Stitt
No relevant relationships to disclose
A. O'Connell
No relevant relationships to disclose
M. J. MacKenzie
Consultant or Advisory Role - Roche
Honoraria - Roche
W. I. Kocha
Consultant or Advisory Role - Novartis
Honoraria - Novartis
I. G. Kerr
No relevant relationships to disclose
B. H. Dingle
No relevant relationships to disclose
A. Malpage
No relevant relationships to disclose